<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35341975</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1878-1519</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>301</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Respiratory physiology &amp; neurobiology</Title>
          <ISOAbbreviation>Respir Physiol Neurobiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>MiR-21 modulates proliferation and apoptosis of human airway smooth muscle cells by regulating autophagy via PARP-1/AMPK/mTOR signalling pathway.</ArticleTitle>
        <Pagination>
          <StartPage>103891</StartPage>
          <MedlinePgn>103891</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.resp.2022.103891</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1569-9048(22)00050-7</ELocationID>
        <Abstract>
          <AbstractText>Superfluous human airway smooth muscle (HASM) cell proliferation is an important pathological feature of airway remodelling in asthma. This study aimed to determine whether miR-21 is involved in the regulation of HASM cell survival. Overexpressed miR-21 inhibited HASM cell apoptosis and autophagy and promoted proliferation, whereas a miR-21 inhibitor exerted the opposite effects (P &lt; 0.05). Overexpressed poly (ADP-ribose) polymerase-1 (PARP-1) promoted apoptosis and inhibited proliferation of HASM cells (P &lt; 0.05). Dual-luciferase assays confirmed that miR-21 directly targeted poly (ADP-ribose) polymerase-1 (PARP-1) mRNA (P &lt; 0.05). Silencing PARP-1 based on miR-21 downregulation mimicked the role of 3-methyladenine (3-MA), an autophagy inhibitor (P &lt; 0.05). Overexpressed PARP-1 reversed the effects of miR-21 on HASM cells, somewhat dependently on PARP-1-induced enhanced autophagy, which we elucidated by 3-MA block (P &lt; 0.05). MicroRNA-21 mimics reduced AMPK and increased mTOR signalling by downregulating PARP-1, and a miR-21 inhibitor exerted the opposite effects (P &lt; 0.05). Collectively, miR-21 inhibitor could upregulate PARP-1 in HASM cells to promote autophagy and thus inhibit proliferation and promote apoptosis that might be mediated by the AMPK/mTOR signalling pathway.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Peng</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, 29 Xinglong Road, Changzhou 213003, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Shiqing</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, 29 Xinglong Road, Changzhou 213003, China; Dalian Medical University, Dalian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Di</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, 29 Xinglong Road, Changzhou 213003, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qian</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, 29 Xinglong Road, Changzhou 213003, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiao</LastName>
            <ForeName>Xinru</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, 29 Xinglong Road, Changzhou 213003, China; Dalian Medical University, Dalian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Qian</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, 29 Xinglong Road, Changzhou 213003, China. Electronic address: qianzhang@njmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Respir Physiol Neurobiol</MedlineTA>
        <NlmUniqueID>101140022</NlmUniqueID>
        <ISSNLinking>1569-9048</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C524940">MIRN21 microRNA, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000067856">Poly(ADP-ribose) Polymerase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.4.2.30</RegistryNumber>
          <NameOfSubstance UI="D000071137">Poly (ADP-Ribose) Polymerase-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.31</RegistryNumber>
          <NameOfSubstance UI="D055372">AMP-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D055372" MajorTopicYN="Y">AMP-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032389" MajorTopicYN="N">Myocytes, Smooth Muscle</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071137" MajorTopicYN="N">Poly (ADP-Ribose) Polymerase-1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000067856" MajorTopicYN="N">Poly(ADP-ribose) Polymerase Inhibitors</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">AMPK/mTOR signalling pathway</Keyword>
        <Keyword MajorTopicYN="N">Asthma</Keyword>
        <Keyword MajorTopicYN="N">Autophagy</Keyword>
        <Keyword MajorTopicYN="N">Human airway smooth muscle cell</Keyword>
        <Keyword MajorTopicYN="N">MiR-21</Keyword>
        <Keyword MajorTopicYN="N">Poly (ADP-ribose) polymerase-1</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>28</Day>
          <Hour>5</Hour>
          <Minute>29</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35341975</ArticleId>
        <ArticleId IdType="doi">10.1016/j.resp.2022.103891</ArticleId>
        <ArticleId IdType="pii">S1569-9048(22)00050-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35341975</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1878-1519</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>301</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Respiratory physiology &amp; neurobiology</Title>
          <ISOAbbreviation>Respir Physiol Neurobiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>MiR-21 modulates proliferation and apoptosis of human airway smooth muscle cells by regulating autophagy via PARP-1/AMPK/mTOR signalling pathway.</ArticleTitle>
        <Pagination>
          <StartPage>103891</StartPage>
          <MedlinePgn>103891</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.resp.2022.103891</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1569-9048(22)00050-7</ELocationID>
        <Abstract>
          <AbstractText>Superfluous human airway smooth muscle (HASM) cell proliferation is an important pathological feature of airway remodelling in asthma. This study aimed to determine whether miR-21 is involved in the regulation of HASM cell survival. Overexpressed miR-21 inhibited HASM cell apoptosis and autophagy and promoted proliferation, whereas a miR-21 inhibitor exerted the opposite effects (P &lt; 0.05). Overexpressed poly (ADP-ribose) polymerase-1 (PARP-1) promoted apoptosis and inhibited proliferation of HASM cells (P &lt; 0.05). Dual-luciferase assays confirmed that miR-21 directly targeted poly (ADP-ribose) polymerase-1 (PARP-1) mRNA (P &lt; 0.05). Silencing PARP-1 based on miR-21 downregulation mimicked the role of 3-methyladenine (3-MA), an autophagy inhibitor (P &lt; 0.05). Overexpressed PARP-1 reversed the effects of miR-21 on HASM cells, somewhat dependently on PARP-1-induced enhanced autophagy, which we elucidated by 3-MA block (P &lt; 0.05). MicroRNA-21 mimics reduced AMPK and increased mTOR signalling by downregulating PARP-1, and a miR-21 inhibitor exerted the opposite effects (P &lt; 0.05). Collectively, miR-21 inhibitor could upregulate PARP-1 in HASM cells to promote autophagy and thus inhibit proliferation and promote apoptosis that might be mediated by the AMPK/mTOR signalling pathway.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Peng</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, 29 Xinglong Road, Changzhou 213003, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Shiqing</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, 29 Xinglong Road, Changzhou 213003, China; Dalian Medical University, Dalian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Di</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, 29 Xinglong Road, Changzhou 213003, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qian</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, 29 Xinglong Road, Changzhou 213003, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xiao</LastName>
            <ForeName>Xinru</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, 29 Xinglong Road, Changzhou 213003, China; Dalian Medical University, Dalian, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Qian</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Respiratory and Critical Care Medicine, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, 29 Xinglong Road, Changzhou 213003, China. Electronic address: qianzhang@njmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Respir Physiol Neurobiol</MedlineTA>
        <NlmUniqueID>101140022</NlmUniqueID>
        <ISSNLinking>1569-9048</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C524940">MIRN21 microRNA, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000067856">Poly(ADP-ribose) Polymerase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.4.2.30</RegistryNumber>
          <NameOfSubstance UI="D000071137">Poly (ADP-Ribose) Polymerase-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.31</RegistryNumber>
          <NameOfSubstance UI="D055372">AMP-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D055372" MajorTopicYN="Y">AMP-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032389" MajorTopicYN="N">Myocytes, Smooth Muscle</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071137" MajorTopicYN="N">Poly (ADP-Ribose) Polymerase-1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000067856" MajorTopicYN="N">Poly(ADP-ribose) Polymerase Inhibitors</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">AMPK/mTOR signalling pathway</Keyword>
        <Keyword MajorTopicYN="N">Asthma</Keyword>
        <Keyword MajorTopicYN="N">Autophagy</Keyword>
        <Keyword MajorTopicYN="N">Human airway smooth muscle cell</Keyword>
        <Keyword MajorTopicYN="N">MiR-21</Keyword>
        <Keyword MajorTopicYN="N">Poly (ADP-ribose) polymerase-1</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>28</Day>
          <Hour>5</Hour>
          <Minute>29</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35341975</ArticleId>
        <ArticleId IdType="doi">10.1016/j.resp.2022.103891</ArticleId>
        <ArticleId IdType="pii">S1569-9048(22)00050-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
